Akorn

Lundbeck recently sold pentobarbital, under the trade name Nembutal, to an American company called Akorn.

US pharmaceutical firm Hospira under fire over use of its drugs in executions 2012

But it did so only on the condition that Akorn continued the restricted distribution system.

US pharmaceutical firm Hospira under fire over use of its drugs in executions 2012

Akorn stock soared as much as 53% Wednesday before settling up 35 cents, or 18%, to 2.30 after the joint venture it formed with India-based Strides Arcolab was granted approvals for two of its generic antibiotic products by the Food and Drug Administration.

Small Stocks Joined In On End-of-Year Buying 2009

Former Akorn Officer Loses Appeal A former Akorn Inc. chief financial officer lost an appeal to overturn an administrative sanction by the Securities and Exchange Commission over her approval of a year 2000 financial report that inflated the company's results.

High Court Declines to Hear 2007

Akorn restated its results for 2000 and 2001 in October 2002, saying it had understated expenses for bad debts.

High Court Declines to Hear 2007

Rita McConville, the former Akorn officer, was sanctioned in an administrative proceeding with a cease-and-desist order.

High Court Declines to Hear 2007

Recently, tiny drug firm Akorn and India-based Cipla said they reached an agreement to develop a generic oral anti-infective agent that analysts speculate could be generic Vancocin.

ViroPharma's Generic Worries Create Attractive Entry Point 2006

Earlier this week, tiny drug developer Akorn and India-based Cipla said they had forged an agreement to develop a generic oral anti-infective agent which is thought to be generic Vancocin, according to Piper Jaffray.

ViroPharma's Sales Estimates Still 'Highly Conservative' 2006

In addition, Akorn's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies.

unknown title 2011

This press release includes statements that may constitute "forward-looking statements", including projections of certain measures of Akorn's results of operations, projections of certain charges and expenses, and other statements regarding Akorn's goals, regulatory approvals and strategy.

unknown title 2011